海外の治験の状況「1」での検索結果
148件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Infants with Type1 Spinal Muscular Atrophy
- Type 1 Spinal Muscular Atrophy (SMA) br>MedDRA version: 20.1 Level: PT Classification code 10041582 Term: Spinal muscular atrophy System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Belgium, Brazil, Canada, China, Croatia, France, Germany, Italy, Japan, Lebanon, Poland, Russian Federation, Saudi Arabia, Serbia, Spain, Switzerland, Turkey, Ukraine, United Kingdom, United States
- 2016-07-21
Authorised
- Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Crohn’s Disease, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo.
- Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Switzerland, Ukraine, United Kingdom, United States
- 2018-04-20
Authorised
- Studio internazionale per il trattamento della leucemia linfoblastica acuta Philadelphia positiva
- Leucemia Linfoblastica Acuta Ph + MedDRA version: 20.1 Level: LLT Classification code 10000844 Term: Acute lymphoblastic leukaemia System Organ Class: 100000004864 MedDRA version: 20.1 Level: PT Classification code 10034877 Term: Philadelphia chromosome positive System Organ Class: 10022891 - Investigations ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Canada, Chile, European Union, Hong Kong, Israel, Italy, Switzerland, United States
- 2018-02-12
Authorised
- This is a study to evaluate the safety and effectiveness of Tolvaptan in adults with chronic kidney disease
- Autosomal Dominant Polycystic Kidney Disease (ADPKD) MedDRA version: 18.1 Level: LLT Classification code 10036046 Term: Polycystic kidney, autosomal dominant System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, France, Germany, Hungary, Israel, Italy, Korea, Republic of, Malaysia, Mexico, Netherlands, Norway, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States
- 2014-07-31
Authorised
- This is a study to evaluate the long term safety of Tolvaptan in adults with chronic kidney disease.
- Autosomal Dominant Polycystic Kidney Disease (ADPKD) MedDRA version: 20.0 Level: LLT Classification code 10036046 Term: Polycystic kidney, autosomal dominant System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, France, Germany, Hungary, Israel, Italy, Mexico, Netherlands, Norway, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Sweden, Switzerland, United Kingdom, United States
- 2014-09-30
Authorised
- Phase 3 Study of Pembrolizumab/Epacadostat/Chemotherapy in Metastatic NSCLC
- First-line treatment of metastatic NSCLC MedDRA version: 20.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Brazil, Canada, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2017-11-02
Authorised
- 207966 or "ATLAS-2M" is a study to compare two drugs called Cabotegravir and Rilpivirine when given as long acting injections either every 8 weeks or every 4 weeks in adults with HIV.
- Human Immunodeficiency Virus type 1 (HIV-1) MedDRA version: 20.1 Level: LLT Classification code 10003582 Term: Asymptomatic human immunodeficiency virus type I infection System Organ Class: 100000004862 ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Argentina, Australia, Canada, France, Germany, Italy, Korea, Democratic People's Republic of, Mexico, Russian Federation, South Africa, Spain, Sweden, United States
- 2017-10-18
Authorised
- 207966 or "ATLAS-2M" is a study to compare two drugs called Cabotegravir and Rilpivirine when given as long acting injections either every 8 weeks or every 4 weeks in adults with HIV.
- Human Immunodeficiency Virus type 1 (HIV-1) MedDRA version: 20.0 Level: LLT Classification code 10003582 Term: Asymptomatic human immunodeficiency virus type I infection System Organ Class: 100000020183 ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Argentina, Australia, Canada, France, Germany, Italy, Korea, Democratic People's Republic of, Mexico, Russian Federation, South Africa, Spain, Sweden, United States
- 2017-09-18
Authorised
- A Phase 3 study to investigate Efficacy and Safety of BGB-A317 in patients with Non-Small Cell Lung Cancer
- Previously treated Non-Small Cell Lung Cancer in the second or third line setting. MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Brazil, Bulgaria, China, Lithuania, Mexico, New Zealand, Poland, Russian Federation, Slovakia, Turkey
- 2018-05-28
Authorised
- Phase 3 Study of Pembrolizumab/Epacadostat/Chemotherapy in Metastatic NSCLC
- First-line treatment of metastatic NSCLC MedDRA version: 20.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Brazil, Canada, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2018-03-12